View Future GrowthKronox Lab Sciences 過去の業績この会社の最新の決算報告書はまだ処理中です過去 基準チェック /36Kronox Lab Sciencesは、平均年間17.7%の収益成長を遂げていますが、 Chemicals業界の収益は、年間 成長しています。収益は、平均年間6.7% 7.3%収益成長率で 成長しています。 Kronox Lab Sciencesの自己資本利益率は25.6%であり、純利益率は25.7%です。主要情報17.68%収益成長率18.80%EPS成長率Chemicals 業界の成長17.68%収益成長率7.34%株主資本利益率25.61%ネット・マージン25.66%前回の決算情報31 Dec 2025最近の業績更新お知らせ • May 15Kronox Lab Sciences Limited to Report Q4, 2026 Results on May 20, 2026Kronox Lab Sciences Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 20, 2026Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.お知らせ • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: ₹1.82 (vs ₹1.76 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.82 (up from ₹1.76 in 2Q 2025). Revenue: ₹265.8m (up 6.9% from 2Q 2025). Net income: ₹66.8m (up 3.1% from 2Q 2025). Profit margin: 25% (in line with 2Q 2025).お知らせ • Nov 04Kronox Lab Sciences Limited to Report Q2, 2026 Results on Nov 11, 2025Kronox Lab Sciences Limited announced that they will report Q2, 2026 results on Nov 11, 2025お知らせ • Aug 06Kronox Lab Sciences Limited to Report Q1, 2026 Results on Aug 11, 2025Kronox Lab Sciences Limited announced that they will report Q1, 2026 results on Aug 11, 2025すべての更新を表示Recent updatesお知らせ • May 15Kronox Lab Sciences Limited to Report Q4, 2026 Results on May 20, 2026Kronox Lab Sciences Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 20, 2026Buy Or Sell Opportunity • Apr 06Now 27% overvaluedOver the last 90 days, the stock has fallen 5.1% to ₹132. The fair value is estimated to be ₹104, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹118, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.お知らせ • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: ₹1.82 (vs ₹1.76 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.82 (up from ₹1.76 in 2Q 2025). Revenue: ₹265.8m (up 6.9% from 2Q 2025). Net income: ₹66.8m (up 3.1% from 2Q 2025). Profit margin: 25% (in line with 2Q 2025).お知らせ • Nov 04Kronox Lab Sciences Limited to Report Q2, 2026 Results on Nov 11, 2025Kronox Lab Sciences Limited announced that they will report Q2, 2026 results on Nov 11, 2025Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Non Executive-Independent Women Director Krutika Negandhi was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 06Kronox Lab Sciences Limited to Report Q1, 2026 Results on Aug 11, 2025Kronox Lab Sciences Limited announced that they will report Q1, 2026 results on Aug 11, 2025Upcoming Dividend • Aug 01Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 08 August 2025. Payment date: 17 September 2025. Payout ratio is a comfortable 7.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).Reported Earnings • Jul 29Full year 2025 earnings released: EPS: ₹6.86 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.86 (up from ₹5.75 in FY 2024). Revenue: ₹1.00b (up 12% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.お知らせ • Jul 28Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025, at 11:00 Indian Standard Time.お知らせ • Jul 26Kronox Lab Sciences Limited announces Annual dividend, payable on September 17, 2025Kronox Lab Sciences Limited announced Annual dividend of INR 0.5000 per share payable on September 17, 2025, ex-date on August 08, 2025 and record date on August 08, 2025.Buy Or Sell Opportunity • Jul 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to ₹202. The fair value is estimated to be ₹168, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 22%.Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹188, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 25% over the past year.Valuation Update With 7 Day Price Move • May 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹172, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 27x in the Chemicals industry in India.Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹6.91 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.91 (up from ₹5.75 in FY 2024). Revenue: ₹1.03b (up 14% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.お知らせ • May 19Kronox Lab Sciences Limited to Report Q4, 2025 Results on May 22, 2025Kronox Lab Sciences Limited announced that they will report Q4, 2025 results on May 22, 2025Reported Earnings • Feb 02Third quarter 2025 earnings released: EPS: ₹1.77 (vs ₹1.29 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.77 (up from ₹1.29 in 3Q 2024). Revenue: ₹248.3m (up 20% from 3Q 2024). Net income: ₹65.3m (up 38% from 3Q 2024). Profit margin: 26% (up from 23% in 3Q 2024). The increase in margin was driven by higher revenue.お知らせ • Jan 23Kronox Lab Sciences Limited to Report Q3, 2025 Results on Jan 31, 2025Kronox Lab Sciences Limited announced that they will report Q3, 2025 results on Jan 31, 2025Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹191, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 32x in the Chemicals industry in India.New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (₹6.87b market cap, or US$81.4m).お知らせ • Oct 31Kronox Lab Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024Kronox Lab Sciences Limited announced that they will report Q2, 2025 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹175, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 35x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Aug 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹182, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 36x in the Chemicals industry in India.お知らせ • Aug 09Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024, at 11:00 Indian Standard Time. Location: Block no. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 IndiaReported Earnings • Aug 07First quarter 2025 earnings released: EPS: ₹1.67 (vs ₹0.64 in 1Q 2024)First quarter 2025 results: EPS: ₹1.67 (up from ₹0.64 in 1Q 2024). Revenue: ₹256.2m (up 19% from 1Q 2024). Net income: ₹61.5m (up 152% from 1Q 2024). Profit margin: 24% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue.お知らせ • Jul 29Kronox Lab Sciences Limited to Report Q1, 2025 Results on Aug 06, 2024Kronox Lab Sciences Limited announced that they will report Q1, 2025 results on Aug 06, 2024お知らせ • Jun 22Kronox Lab Sciences Limited to Report Q4, 2024 Results on Jun 28, 2024Kronox Lab Sciences Limited announced that they will report Q4, 2024 results on Jun 28, 2024Board Change • Jun 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Satish Kumar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.収支内訳Kronox Lab Sciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BSE:544187 収益、費用、利益 ( )INR Millions日付収益収益G+A経費研究開発費31 Dec 251,01226070030 Sep 251,00025960030 Jun 2599325654031 Mar 251,00225548031 Dec 2496225047030 Sep 2492923249030 Jun 2489121156031 Mar 2489921462031 Dec 2389218069031 Mar 2395616470031 Mar 2282413658031 Mar 216269754031 Mar 2050885520質の高い収益: 544187は 高品質の収益 を持っています。利益率の向上: 544187の現在の純利益率 (25.7%)は、昨年(26%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 544187の収益は過去 5 年間で年間17.7%増加しました。成長の加速: 544187の過去 1 年間の収益成長率 ( 3.8% ) は、5 年間の平均 ( 年間17.7%を下回っています。収益対業界: 544187の過去 1 年間の収益成長率 ( 3.8% ) Chemicals業界10.1%を上回りませんでした。株主資本利益率高いROE: 544187の 自己資本利益率 ( 25.6% ) は 高い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 06:48終値2026/05/22 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kronox Lab Sciences Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 15Kronox Lab Sciences Limited to Report Q4, 2026 Results on May 20, 2026Kronox Lab Sciences Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 20, 2026
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.
お知らせ • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026
Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: ₹1.82 (vs ₹1.76 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.82 (up from ₹1.76 in 2Q 2025). Revenue: ₹265.8m (up 6.9% from 2Q 2025). Net income: ₹66.8m (up 3.1% from 2Q 2025). Profit margin: 25% (in line with 2Q 2025).
お知らせ • Nov 04Kronox Lab Sciences Limited to Report Q2, 2026 Results on Nov 11, 2025Kronox Lab Sciences Limited announced that they will report Q2, 2026 results on Nov 11, 2025
お知らせ • Aug 06Kronox Lab Sciences Limited to Report Q1, 2026 Results on Aug 11, 2025Kronox Lab Sciences Limited announced that they will report Q1, 2026 results on Aug 11, 2025
お知らせ • May 15Kronox Lab Sciences Limited to Report Q4, 2026 Results on May 20, 2026Kronox Lab Sciences Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 20, 2026
Buy Or Sell Opportunity • Apr 06Now 27% overvaluedOver the last 90 days, the stock has fallen 5.1% to ₹132. The fair value is estimated to be ₹104, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹118, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.
お知らせ • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026
Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: ₹1.82 (vs ₹1.76 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.82 (up from ₹1.76 in 2Q 2025). Revenue: ₹265.8m (up 6.9% from 2Q 2025). Net income: ₹66.8m (up 3.1% from 2Q 2025). Profit margin: 25% (in line with 2Q 2025).
お知らせ • Nov 04Kronox Lab Sciences Limited to Report Q2, 2026 Results on Nov 11, 2025Kronox Lab Sciences Limited announced that they will report Q2, 2026 results on Nov 11, 2025
Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Non Executive-Independent Women Director Krutika Negandhi was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 06Kronox Lab Sciences Limited to Report Q1, 2026 Results on Aug 11, 2025Kronox Lab Sciences Limited announced that they will report Q1, 2026 results on Aug 11, 2025
Upcoming Dividend • Aug 01Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 08 August 2025. Payment date: 17 September 2025. Payout ratio is a comfortable 7.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).
Reported Earnings • Jul 29Full year 2025 earnings released: EPS: ₹6.86 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.86 (up from ₹5.75 in FY 2024). Revenue: ₹1.00b (up 12% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.
お知らせ • Jul 28Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025, at 11:00 Indian Standard Time.
お知らせ • Jul 26Kronox Lab Sciences Limited announces Annual dividend, payable on September 17, 2025Kronox Lab Sciences Limited announced Annual dividend of INR 0.5000 per share payable on September 17, 2025, ex-date on August 08, 2025 and record date on August 08, 2025.
Buy Or Sell Opportunity • Jul 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to ₹202. The fair value is estimated to be ₹168, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 22%.
Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹188, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 25% over the past year.
Valuation Update With 7 Day Price Move • May 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹172, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 27x in the Chemicals industry in India.
Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹6.91 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.91 (up from ₹5.75 in FY 2024). Revenue: ₹1.03b (up 14% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.
お知らせ • May 19Kronox Lab Sciences Limited to Report Q4, 2025 Results on May 22, 2025Kronox Lab Sciences Limited announced that they will report Q4, 2025 results on May 22, 2025
Reported Earnings • Feb 02Third quarter 2025 earnings released: EPS: ₹1.77 (vs ₹1.29 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.77 (up from ₹1.29 in 3Q 2024). Revenue: ₹248.3m (up 20% from 3Q 2024). Net income: ₹65.3m (up 38% from 3Q 2024). Profit margin: 26% (up from 23% in 3Q 2024). The increase in margin was driven by higher revenue.
お知らせ • Jan 23Kronox Lab Sciences Limited to Report Q3, 2025 Results on Jan 31, 2025Kronox Lab Sciences Limited announced that they will report Q3, 2025 results on Jan 31, 2025
Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹191, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 32x in the Chemicals industry in India.
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (₹6.87b market cap, or US$81.4m).
お知らせ • Oct 31Kronox Lab Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024Kronox Lab Sciences Limited announced that they will report Q2, 2025 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹175, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 35x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Aug 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹182, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 36x in the Chemicals industry in India.
お知らせ • Aug 09Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024, at 11:00 Indian Standard Time. Location: Block no. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 India
Reported Earnings • Aug 07First quarter 2025 earnings released: EPS: ₹1.67 (vs ₹0.64 in 1Q 2024)First quarter 2025 results: EPS: ₹1.67 (up from ₹0.64 in 1Q 2024). Revenue: ₹256.2m (up 19% from 1Q 2024). Net income: ₹61.5m (up 152% from 1Q 2024). Profit margin: 24% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue.
お知らせ • Jul 29Kronox Lab Sciences Limited to Report Q1, 2025 Results on Aug 06, 2024Kronox Lab Sciences Limited announced that they will report Q1, 2025 results on Aug 06, 2024
お知らせ • Jun 22Kronox Lab Sciences Limited to Report Q4, 2024 Results on Jun 28, 2024Kronox Lab Sciences Limited announced that they will report Q4, 2024 results on Jun 28, 2024
Board Change • Jun 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Satish Kumar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.